Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,757 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Giredestrant reverses progesterone hypersensitivity driven by estrogen receptor mutations in breast cancer.
Liang J, Ingalla ER, Yao X, Wang BE, Tai L, Giltnane J, Liang Y, Daemen A, Moore HM, Aimi J, Chang CW, Gates MR, Eng-Wong J, Tam L, Bacarro N, Roose-Girma M, Bellet M, Hafner M, Metcalfe C. Liang J, et al. Among authors: chang cw. Sci Transl Med. 2022 Sep 21;14(663):eabo5959. doi: 10.1126/scitranslmed.abo5959. Epub 2022 Sep 21. Sci Transl Med. 2022. PMID: 36130016
Low-pass Whole-genome Sequencing of Circulating Cell-free DNA Demonstrates Dynamic Changes in Genomic Copy Number in a Squamous Lung Cancer Clinical Cohort.
Chen X, Chang CW, Spoerke JM, Yoh KE, Kapoor V, Baudo C, Aimi J, Yu M, Liang-Chu MMY, Suttmann R, Huw LY, Gendreau S, Cummings C, Lackner MR. Chen X, et al. Among authors: chang cw. Clin Cancer Res. 2019 Apr 1;25(7):2254-2263. doi: 10.1158/1078-0432.CCR-18-1593. Epub 2019 Jan 7. Clin Cancer Res. 2019. PMID: 30617129
Comprehensive Profiling of Poor-Risk Paired Primary and Recurrent Triple-Negative Breast Cancers Reveals Immune Phenotype Shifts.
Hutchinson KE, Yost SE, Chang CW, Johnson RM, Carr AR, McAdam PR, Halligan DL, Chang CC, Schmolze D, Liang J, Yuan Y. Hutchinson KE, et al. Among authors: chang cw, chang cc. Clin Cancer Res. 2020 Feb 1;26(3):657-668. doi: 10.1158/1078-0432.CCR-19-1773. Epub 2019 Oct 14. Clin Cancer Res. 2020. PMID: 31611282 Free PMC article.
A Phase I Study of DLYE5953A, an Anti-LY6E Antibody Covalently Linked to Monomethyl Auristatin E, in Patients with Refractory Solid Tumors.
Tolaney SM, Do KT, Eder JP, LoRusso PM, Weekes CD, Chandarlapaty S, Chang CW, Chen SC, Nazzal D, Schuth E, Brunstein F, Carrasco-Triguero M, Darbonne WC, Giltnane JM, Flanagan WM, Commerford SR, Ungewickell A, Shapiro GI, Modi S. Tolaney SM, et al. Among authors: chang cw. Clin Cancer Res. 2020 Nov 1;26(21):5588-5597. doi: 10.1158/1078-0432.CCR-20-1067. Epub 2020 Jul 21. Clin Cancer Res. 2020. PMID: 32694157 Free PMC article. Clinical Trial.
Integrated digital pathology and transcriptome analysis identifies molecular mediators of T-cell exclusion in ovarian cancer.
Desbois M, Udyavar AR, Ryner L, Kozlowski C, Guan Y, Dürrbaum M, Lu S, Fortin JP, Koeppen H, Ziai J, Chang CW, Keerthivasan S, Plante M, Bourgon R, Bais C, Hegde P, Daemen A, Turley S, Wang Y. Desbois M, et al. Among authors: chang cw. Nat Commun. 2020 Nov 4;11(1):5583. doi: 10.1038/s41467-020-19408-2. Nat Commun. 2020. PMID: 33149148 Free PMC article.
The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 -) advanced/metastatic breast cancer.
Bardia A, Mayer I, Winer E, Linden HM, Ma CX, Parker BA, Bellet M, Arteaga CL, Cheeti S, Gates M, Chang CW, Fredrickson J, Spoerke JM, Moore HM, Giltnane J, Friedman LS, Chow Maneval E, Chan I, Jhaveri K. Bardia A, et al. Among authors: chang cw. Breast Cancer Res Treat. 2023 Jan;197(2):319-331. doi: 10.1007/s10549-022-06797-9. Epub 2022 Nov 19. Breast Cancer Res Treat. 2023. PMID: 36401732 Free PMC article.
An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer.
Chandarlapaty S, Dickler MN, Perez Fidalgo JA, Villanueva-Vázquez R, Giltnane J, Gates M, Chang CW, Cheeti S, Fredrickson J, Wang X, Collier A, Moore HM, Metcalfe C, Lauchle J, Humke EW, Bardia A. Chandarlapaty S, et al. Among authors: chang cw. Clin Cancer Res. 2023 Aug 1;29(15):2781-2790. doi: 10.1158/1078-0432.CCR-23-0011. Clin Cancer Res. 2023. PMID: 37261814 Free PMC article. Clinical Trial.
Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor-Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer.
Jhaveri KL, Bellet M, Turner NC, Loi S, Bardia A, Boni V, Sohn J, Neilan TG, Villanueva-Vázquez R, Kabos P, García-Estévez L, López-Miranda E, Pérez-Fidalgo JA, Pérez-García JM, Yu J, Fredrickson J, Moore HM, Chang CW, Bond JW, Eng-Wong J, Gates MR, Lim E. Jhaveri KL, et al. Among authors: chang cw. Clin Cancer Res. 2024 Feb 16;30(4):754-766. doi: 10.1158/1078-0432.CCR-23-1796. Clin Cancer Res. 2024. PMID: 37921755 Free PMC article. Clinical Trial.
Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy.
Li X, Eastham J, Giltnane JM, Zou W, Zijlstra A, Tabatsky E, Banchereau R, Chang CW, Nabet BY, Patil NS, Molinero L, Chui S, Harryman M, Lau S, Rangell L, Waumans Y, Kockx M, Orlova D, Koeppen H. Li X, et al. Among authors: chang cw. J Pathol. 2024 Jun;263(2):190-202. doi: 10.1002/path.6274. Epub 2024 Mar 25. J Pathol. 2024. PMID: 38525811
1,757 results